Vertex Prescription drugs stated Thursday that its carefully watched drug, suzetrigine, lowered ache in comparison with baseline however didn’t outperform a placebo in a Part 2 research, elevating doubts concerning the medication’s potential within the profitable marketplace for treating continual ache.
The corporate stated in a press launch that it believes addressing variability amongst responses in placebo sufferers by higher designing its scientific trials might enable suzetrigine to achieve a future Part 3 research.
Researchers gave suzetrigine to 102 sufferers with lumbosacral radiculopathy (LSR), a situation through which compressed nerves within the backbone result in again and leg ache. The principle purpose of the research was lowering these sufferers’ ache as measured by the numeric ache ranking scale, which asks sufferers to rank ache from 0 (no ache) to 10 (the worst ache conceivable).
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
